NEW YORK (GenomeWeb News) – Pfizer will use Odyssey Thera’s cell-based protein-fragment complementation assay (PCA) technology to evaluate the selectivity of Pfizer compounds, Odyssey said today.
Under the terms of the agreement, Odyssey will receive an upfront payment, research and capital expenditure funding, and success-based milestone payments. Further financial details were not disclosed.
The current research collaboration will focus on “large numbers” of Pfizer chemical leads and drug candidates from multiple therapeutic areas, Odyssey said. Odyssey and Pfizer will use the PCA technology and other assays based on automated microscopy to measure changes in cellular signaling networks in response to Pfizer compounds.
The agreement expands upon a May 2005 collaboration between the companies to profile certain Pfizer compounds using the PCA technology.